– LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care – Second registrational Phase 3 study, SynAIRgy, to begin enrollment in 4th quarter...
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new oral treatment for Obstructive Sleep Apnea CAMBRIDGE, Mass. September 18, 2023 – Apnimed, a clinical-stage pharmaceutical company focused on...
– New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from the Oxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month – Exploratory Trial on the Impact of Investigational Combination AD113 on OSA Severity and Blood Pressure in...
CAMBRIDGE, Mass. August 30, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
CAMBRIDGE, Mass. August 28, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
